Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
Panoutsopoulou K, Avgeris M, Magkou P, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Loverix L, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. Panoutsopoulou K, et al. Among authors: loverix l. Int J Cancer. 2020 Dec 15;147(12):3560-3573. doi: 10.1002/ijc.33182. Epub 2020 Aug 1. Int J Cancer. 2020. PMID: 32621752
Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer.
Kasimir-Bauer S, Roder J, Obermayr E, Mahner S, Vergote I, Loverix L, Braicu E, Sehouli J, Concin N, Kimmig R, Net L, Roder H, Zeillinger R, Aust S, On Behalf Of The Ovcad Ovarian Cancer Diagnosis Initiative. Kasimir-Bauer S, et al. Among authors: loverix l. Cancers (Basel). 2020 Sep 4;12(9):2519. doi: 10.3390/cancers12092519. Cancers (Basel). 2020. PMID: 32899818 Free PMC article.
High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S, Busschaert P, Qian J, Vanderstichele A, Loverix L, Van Gorp T, Van Nieuwenhuysen E, Han S, Van den Broeck A, Coosemans A, Van Rompuy AS, Lambrechts D, Vergote I. Olbrecht S, et al. Among authors: loverix l. Genome Med. 2021 Jul 9;13(1):111. doi: 10.1186/s13073-021-00922-x. Genome Med. 2021. PMID: 34238352 Free PMC article.
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
Vanderstichele A, Loverix L, Busschaert P, Van Nieuwenhuysen E, Han SN, Concin N, Callewaert T, Olbrecht S, Salihi R, Berteloot P, Neven P, Lambrechts D, Van Gorp T, Vergote I. Vanderstichele A, et al. Among authors: loverix l. Gynecol Oncol. 2022 Apr;165(1):14-22. doi: 10.1016/j.ygyno.2022.01.034. Epub 2022 Feb 14. Gynecol Oncol. 2022. PMID: 35177277 Clinical Trial.
Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer.
Vanderstichele A, Busschaert P, Landolfo C, Olbrecht S, Coosemans A, Froyman W, Loverix L, Concin N, Braicu EI, Wimberger P, Van Nieuwenhuysen E, Han SN, Van Gorp T, Venken T, Heremans R, Neven P, Bourne T, Van Calster B, Timmerman D, Lambrechts D, Vergote I. Vanderstichele A, et al. Among authors: loverix l. NPJ Genom Med. 2022 Apr 28;7(1):30. doi: 10.1038/s41525-022-00300-5. NPJ Genom Med. 2022. PMID: 35484288 Free PMC article.
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCS Group; Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommoss FKF, Kruitwagen RFPM, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut … See abstract for full author list ➔ Kang EY, et al. Among authors: loverix l. Cancer. 2023 Mar 1;129(5):697-713. doi: 10.1002/cncr.34582. Epub 2022 Dec 26. Cancer. 2023. PMID: 36572991 Free PMC article.
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
Loverix L, Vergote I, Busschaert P, Vanderstichele A, Venken T, Boeckx B, Harter P, Brems H, Van Nieuwenhuysen E, Pignata S, Baert T, Gonzalez-Martin A, Han S, Marth C, Neven P, Colombo N, Berteloot P, Mäenpää J, Olbrecht S, Laga T, Sablon E, Ray-Coquard I, Pujade-Lauraine E, Lambrechts D, Van Gorp T. Loverix L, et al. Eur J Cancer. 2023 Jul;188:131-139. doi: 10.1016/j.ejca.2023.04.020. Epub 2023 Apr 27. Eur J Cancer. 2023. PMID: 37245441
13 results